-
Sector Analysis
Ovarian Cancer Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Ovarian Cancer Market Report Overview The ovarian cancer market across the 7MM was valued at $3.3 billion in 2022. The market will grow at a CAGR of more than 1% from 2022 to 2032. The 7MM includes the US, France, Germany, Italy, Spain, the UK, and Japan. Ovarian cancer is one of the most lethal gynecological cancers worldwide. Approximately 90% of ovarian cancer cases are epithelial, with distinct sites of origin arising from the ovarian surface epithelium or distal fallopian...
-
Product Insights
Cervical Cancer Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Cervical Cancer Clinical Trials Analysis Market Overview A total of 2,108 Cervical Cancer clinical trials were conducted as of January 2024. The Cervical Cancer clinical trial report provides a comprehensive understanding of the Cervical Cancer clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       ...
-
Product Insights
Vulvar Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Vulvar Cancer - Drugs In Development, 2023’, provides an overview of the Vulvar Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vulvar Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Vaginal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Vaginal Cancer - Drugs In Development, 2023’, provides an overview of the Vaginal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vaginal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Choriocarcinoma (Gestational Trophoblastic Neoplasia) – Drugs In Development, 2023
Global Markets Direct’s, ‘Choriocarcinoma (Gestational Trophoblastic Neoplasia) - Drugs In Development, 2023’, provides an overview of the Choriocarcinoma (Gestational Trophoblastic Neoplasia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Choriocarcinoma (Gestational Trophoblastic Neoplasia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Sector Analysis
Ovarian Cancer – Cell and Gene Therapies 15-Market Assessment and Forecast to 2031
Ovarian Cancer Cell and Gene Therapy Market Report Overview Ovarian cancer can be broken down into many different types of neoplasms based on specific histopathologic entities and clinical behaviors, and treatment depends on the specific tumor type. Most clinical cases are epithelial ovarian cancers, which represent approximately 90% of diagnosed patients. Ovarian Cancer cell and gene therapy (CGT) market research includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies...